Inceptionr LLC Sells 2,311 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Inceptionr LLC trimmed its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 80.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 551 shares of the company’s stock after selling 2,311 shares during the period. Inceptionr LLC’s holdings in IDEXX Laboratories were worth $228,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Insight Wealth Strategies LLC boosted its holdings in shares of IDEXX Laboratories by 230.5% during the 4th quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company’s stock worth $4,174,000 after buying an additional 7,041 shares during the period. Larson Financial Group LLC boosted its holdings in shares of IDEXX Laboratories by 17,238.5% during the 3rd quarter. Larson Financial Group LLC now owns 2,254 shares of the company’s stock worth $1,139,000 after buying an additional 2,241 shares during the period. Quest Partners LLC boosted its holdings in shares of IDEXX Laboratories by 4,059.4% during the 3rd quarter. Quest Partners LLC now owns 2,870 shares of the company’s stock worth $1,450,000 after buying an additional 2,801 shares during the period. Victory Capital Management Inc. boosted its holdings in shares of IDEXX Laboratories by 3.4% during the 3rd quarter. Victory Capital Management Inc. now owns 142,628 shares of the company’s stock worth $72,059,000 after buying an additional 4,696 shares during the period. Finally, Crystal Rock Capital Management boosted its holdings in shares of IDEXX Laboratories by 90.0% during the 3rd quarter. Crystal Rock Capital Management now owns 9,005 shares of the company’s stock worth $4,550,000 after buying an additional 4,265 shares during the period. 87.84% of the stock is owned by institutional investors.

Insider Activity

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now owns 3,061 shares of the company’s stock, valued at $1,426,242.34. This represents a 49.50 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.11% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Bank of America upped their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. StockNews.com downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Friday. Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Leerink Partners initiated coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They set an “outperform” rating and a $500.00 target price for the company. Finally, Barclays upped their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $533.75.

IDEXX Laboratories Trading Up 1.5 %

Shares of IDXX stock opened at $436.48 on Tuesday. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $562.25. The stock has a market cap of $35.50 billion, a price-to-earnings ratio of 40.91, a P/E/G ratio of 3.41 and a beta of 1.39. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The firm has a fifty day moving average of $437.84 and a 200-day moving average of $448.70.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.